Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA ...
Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous ...
A rare and fatal brain disorder with no available treatment or cure. One that attacks the nervous system, balance, and the ability to move.
Tiziana Life Sciences reported encouraging brain inflammation findings in its MSA study, strengthening attention on ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
The buildup of a protein called 𝛂-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of ...
Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...
In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
MedPage Today on MSN
Is pure autonomic failure a warning sign for Parkinson's? What a new study shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
(MENAFN- GetNews) The Key Multiple System Atrophy Companies in the market include - Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results